Aditxt, Inc. (NASDAQ: ADTX) saw a sharp rise in its stock value after announcing key strategic initiatives. As of the latest pre-market check, ADTX shares were trading at $6.12, up 40.05%, reflecting strong investor confidence.
Advancements in Clinical Trials and Regulatory Efforts
Aditxt provided a corporate update highlighting progress across its subsidiaries. Adimune Inc. is advancing toward clinical trials, having shipped drug substances for ADI-100. It is preparing an Investigational New Drug (IND) application for Stiff Person Syndrome (SPS) in partnership with the Mayo Clinic and a Clinical Trial Application for Type 1 Diabetes (T1D) and Psoriasis in Germany. Clinical trials for these conditions are planned in both Germany and the U.S.
Pearsanta Prepares for IPO and Commercial Launch
Pearsanta, Inc., Aditxt’s precision diagnostics subsidiary, is set for a commercial launch in late 2025, starting with blood-based tests for Prostate Cancer and Endometriosis. The company has engaged Dominari Securities LLC as the lead underwriter for its planned IPO, aiming to fund commercialization and expand its Mitomic Technology platform for early cancer detection. A randomized controlled study for the Mitomic Prostate Test is also in progress.
Adivue Focuses on Neurological Monitoring
Following its acquisition of Brain Scientific assets, Aditxt is launching commercialization efforts through its subsidiary, Adivue, Inc. Adivue is working toward FDA re-approval of Brain Scientific’s electroencephalogram (EEG) device and establishing strategic partnerships for product development and commercial launch.
Strategic Partnerships and Business Expansion
Aditxt has extended its agreement with Appili Therapeutics, Inc. through March 2025, completing the required $250,000 payments. The company is also evaluating additional opportunities with Appili. Similarly, ADTXand Evofem Biosciences, Inc. continue discussions on integrating Evofem into Aditxt’s business acceleration platform.
Commitment to Transparency with Weekly Updates
To enhance communication, the company is launching the Aditxt Weekly Update series on March 21, 2025. The first session will feature a discussion between CEO Amro Albanna and Saundra Pelletier, offering insights into corporate strategy and future plans.
ADTX remains focused on advancing subsidiaries toward key milestones while executing its acquisition strategy, reinforcing its commitment to innovation and growth.